Merck's Pipeline Derisking Accelerates: From KEYTRUDA to a Portfolio of New Blockbusters
Positive readouts for LIPFENDRA, sac-TMT, and tulisokibart, plus the Terns acquisition, are reshaping the growth outlook.
MRK · Earnings Call · 2026-08-04
Strong Price Action on Pipeline Derisking
Merck's shares have rallied 25.6% over the past 90 days, a clear vote of confidence in the company's accelerated pipeline momentum. In the second-quarter call, management framed the quarter as one of "substantial progress" with several clinical milestones hitting "earlier than expected." “Since then, we've made meaningful advancements against that objective, including several important proof points that have occurred earlier than expected.” — Robert Davis, Chairman and Chief Executive Officer · 2026-08-04 The market is recognizing that the KEYTRUDA cliff is becoming a hill, as new products like LIPFENDRA, sac-TMT, and tulisokibart begin to fill the gap.LIPFENDRA: A New Oral Weapon in Cardiovascular Disease
The FDA approval of LIPFENDRA, the first oral PCSK9 inhibitor, is a cornerstone event. President of Research Labs, Dean Li, noted: “The approval of LIPFENDRA is a major milestone in our effort to make PCSK9 inhibition accessible in a convenient daily oral option.” — Dean Li, President, Merck Research Laboratories · 2026-08-04 This product not only expands Merck's cardiometabolic franchise but also capitalizes on evolving Guidelines that lower LDL cholesterol treatment goals. The company is already exploring fixed-dose combinations with rosuvastatin and its oral Lp(a) inhibitor, further broadening the opportunity in the PCSK9 space. The launch is being supported by the FDA's National Priority Voucher process, which accelerated approval by several months.Oncology and Immunology: Sac-TMT and Tulisokibart
In oncology, the TroFuse 005 study for sac-TMT delivered statistically significant improvements in both overall survival and progression-free survival in endometrial cancer. As Dean Li highlighted: “sac-TMT demonstrated statistically significant and clinically meaningful improvement in both overall survival and progression-free survival versus chemotherapy.” — Dean Li, President, Merck Research Laboratories · 2026-08-04 This is the first readout from a 17-study Phase III program, underscoring Merck's ambition to build a differentiated TROP2-directed ADC franchise. In immunology, Tulisokibart met its primary endpoint in the ATLAS-UC induction study, reinforcing the potential of anti-TL1A therapy. The positive data in ulcerative colitis contrasts with a miss in SSc-ILD, which management attributed to a slowly progressing placebo arm. Rob Davis reiterated the long-term growth thesis:we see that as the LOE period is more of a hill than a cliff. Nothing has changed in our view.